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Leukodystrophies are a group of heterogeneous disorders affecting brain myelin. Among
those, childhood ataxia with central nervous system hypomyelination/vanishing white
matter (CACH/VWM) is one of the more common inherited leukodystrophies. Pathogenic
variants in one of the genes encoding ﬁve subunits of EIF2B are associated with CACH/
VWM. Herein, we presented a case of CACH/VWM who developed ataxia following a
minor head injury. Brain magnetic resonance imaging showed extensive white matter
signal abnormality. Diagnosis of CACH/VWM was conﬁrmed by the presence of
compound heterozygous variants in EIF2B3: the previously known pathogenic variant
c c.260C>T (p.Ala87Val) and the novel variant c.673C>T (p.Arg225Trp). Based on the
American College of Medical Genetics (ACMG) recommendations, we classiﬁed
p.Arg225Trp as likely pathogenic. We report a novel variant in a patient with CACH/
VWM and highlight the importance of genetic testing in patients with leukodystrophies.
Keywords: leukodystrophy, childhood ataxia with central nervous system hypomyelination/vanishing white matter,
EIF2B3, ataxia, developmental regression

1 INTRODUCTION
Inherited leukodystrophies (Bonkowsky et al., 2021) are a group of largely heterogeneous genetic
disorders affecting brain myelin (Vanderver et al., 2015). Although individually rare, inherited
leukodystrophies are collectively common with an estimated incidence of 1 in 4,700 live births
(Soderholm et al., 2020). In pediatric population, inherited leukodystrophies cause signiﬁcant
morbidity and mortality, with a mortality rate of 34% and an average age at death of 8.2 years
(Bonkowsky et al., 2010). Leukodystrophies can present at any age, ranging from infancy to
adulthood (Bonkowsky et al., 2021). Disease progression rate and severity vary, even among
affected individuals within the same family. The diagnosis of inherited leukodystrophies relies
on clinical presentation and brain imaging. With the advancement in sequencing technology, genetic
testing has become a part of diagnosis (Soderholm et al., 2020).
Among inherited leukodystrophies, childhood ataxia with central nervous system
hypomyelination/vanishing white matter (CACH/VWM) is one of the more common
leukodystrophies (van der Knaap et al., 1993). In the Netherlands, the estimated incidence is
1 in 80,000 live births (Hamilton et al., 2018). CACH/VWM is characterized by ataxia, loss of
motor skills, and optic atrophy. The patient with CACH/VWM may present at various ages
ranging from fetus to adulthood (Hamilton et al., 2018). Disease progression and age of death are
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2.2 Next-Generation Sequencing

partially correlated with the age of onset. Patients with an onset
age of less than 4 years typically have more rapid progression
and earlier death (Hamilton et al., 2018). The diagnosis of
CACH/VWM is established by brain magnetic resonance
imaging (MRI) and genetic testing. Pathogenic variants in
EIF2B1, EIF2B2, EIF2B3, EIF2B4, and EIF2B5, encoding the
ﬁve subunits of the eukaryotic translation initiation factor 2B
(eIF2B), are found to be associated with CACH/VWM
(Leegwater et al., 2001; van der Knaap et al., 2002).
Herein, we report a child with CACH/VWM who developed
ataxia following minor head trauma. He was found to be
a compound heterozygote for a known pathogenic
variant and a novel variant that is classiﬁed as likely
pathogenic.

Clinical targeted sequencing using the leukodystrophy panel was
performed by Invitae (San Francisco, California). The variants
were conﬁrmed by Sanger sequencing. Bioinformatic analysis was
performed by using combined annotation-dependent depletion
(CADD) (Rentzsch et al., 2019). Variant classiﬁcation was
performed based on American College of Medical Genetics
guidelines (Richards et al., 2015).

3 RESULTS

2 MATERIALS AND METHODS

Two variants were found in EIF2B3, designated as c.260C>T
(p.Ala87Val) and c.673C>T (p.Arg225Trp). Parental testing
conﬁrmed trans conﬁguration (Figure 1B). In silico analysis
supported the deleteriousness of p.Ala87Val and p.Arg225Trp,
with CADD scores of 26.4 and 32, respectively.

2.1 Case Description

4 Follow-Up

Our proband is a male of Northern European ancestry who was
born at term via vaginal delivery. Antenatal and neonatal courses
were uncomplicated. He was meeting developmental milestones
appropriately. At 2 years and 11 months, he had a minor
accidental fall when he fell off the couch. The parents denied
loss of consciousness; however, they noticed that he was unsteady.
He remained unsteady for 3 h after the fall. His gait was
improving over time; however, he remained unstable. He was
referred to orthopedic surgery, and gait ataxia was conﬁrmed.
The child was referred to neurology for further evaluation. The
initial examination was notable for positive Romberg signs with
normal cranial nerve function, muscle tone and strength,
cerebellar signs, and downgoing plantar reﬂex. Brain MRI
revealed diffuse bilateral T2-weighted and FLAIR
hyperintensity in a symmetrical distribution involving the
supratentorial and the cerebellar white matter with sparing of
the basal ganglia (Figure 1A). FLAIR hypointensity was detected
around the ventricle, suggestive of tissue rarefaction. A mild
elevation of the choline peak was detected on MR spectroscopy,
while the lactate peak was absent. Diffusion-weighted imaging
shows subtle diffusion restriction along the margins of the white
matter signal abnormality. Enhancement was not detected
following the administration of contrast. Cerebrospinal ﬂuid
analysis revealed normal glucose, protein, cell count, and
differentiation and negative infectious studies.
Given the concern for leukodystrophy, he was referred to the
genetics service. He was 3 years old at the ﬁrst evaluation. His
weight was at the 83rd percentile, and his height was at the 89th
percentile. His occipitofrontal circumference (OFC) was at the
24th percentile. Neurological examination was notable for
normal mental status, normal cognition, and normal speech
content with mild dysarthria, mild tremor on the ﬁnger-tonose test, mild hyperreﬂexia with normal functional motor
strength, and wide-based gait, but he was able to ambulate
without assistance for 10–12 steps. Biochemical proﬁles
including lysosomal enzyme panel, urine ceramide
trihexoside and sulfatide proﬁles, and leukocyte arylsulfatase A
were normal.

Two months after the ﬁrst evaluation, he developed worsening
ataxia following 2 days of low-grade fever and upper respiratory
infection symptoms. Interval changes in his examination
included worsening hyperreﬂexia, extremity weakness,
intension tremor, and very wide-based gait in addition to
respiratory distress and wheezing on auscultation. He was
admitted for dehydration and monitoring of respiratory status.
He received a course of steroids for 5 days for presumed reactive
airway disease. A follow-up examination demonstrated
resolution of weakness and respiratory symptoms and
improvement of his gait and reﬂexes. He was enrolled in the
clinical trial shortly after his recovery from illness.
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5 DISCUSSION
Herein, we describe a child with CACH/VWM whose symptoms
were triggered by minor head trauma. His MRI demonstrated
diffuse T2 and FLAIR hyperintensity in cerebral white matter
with secondary cavitation, which are typical ﬁndings of CACH/
VWM. He has compound heterozygous variants, namely,
p.Ala87Val and p.Arg225Trp. The variant p.Ala87Val is
known to be pathogenic and is a founder variant among
French–Canadians (Robinson et al., 2014). The residue Ala87
is highly conserved (Figure 1C). A novel variant, p.Arg225Trp,
has been reported in one heterozygote in the population
database (Karczewski et al., 2020). Although its pathogenicity
was unclear, the genetic variant affecting this residue
p.Arg225Gln has been reported to be pathogenic (van der
Knaap et al., 2002). Overexpression of wild-type human
EIF2B3 in eif2b3 mutant zebraﬁsh rescued morphological
phenotypes; however, overexpression of human EIF2B3
harboring pathogenic variants, including p.Ala87Val and
p.Arg225Gln, could not. The residue Arg225 is highly
conserved (Figure 1C). In silico prediction supports that the
change from Arg to Trp is likely to be disruptive (Rentzsch et al.,
2019). Based on American College of Medical Genetics
guidelines for variant classiﬁcation, we classiﬁed p.Arg225Trp
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FIGURE 1 | Brain imaging and pedigree of the proband. (A) T2-weighted MRI of the brain performed at 2 years and 11 months shows diffuse bilateral
hyperintensity with a symmetrical distribution involving the supratentorial (left upper) and the cerebellar white matter (right upper) while sparing the basal ganglia (left
lower). Elevation of the choline peak was detected on MR spectroscopy from the centrum semiovale but not from the basal ganglia (right lower). The proband inherited
biallelic EIF2B3 variants from both parents (B). Both variants are highly conserved (C).

as likely pathogenic using the following criteria: PM2, PM3,
PM5, PP3, and PP4 (Richards et al., 2015).
Our patient presented at the age of 3 years with ataxia
following minor head trauma. The age of 2–4 years is the
most common age of presentation in patients with CACH/
VWM (Hamilton et al., 2018). The majority of the patients in
this group have normal early milestones similar to our patient;
only 9% have delayed early cognitive development (van der
Knaap et al., 2022). The symptoms developed after the
exposure to provocation factors, including fever, head trauma,
and infection, in 72% of the patients in this group (van der Knaap
et al., 2022). Approximately 90% of the patients have an
exacerbated course after the exposure to provocation factors,
in our patient upper respiratory tract infection (van der Knaap
et al., 2022).
A recent study reported a case with CACH/VWM who
received
intravenous
immunoglobulin
and
systemic
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corticosteroids with partial improvement in clinical and
neuroimaging (Singh et al., 2017). Our patient received a short
course of oral steroids primarily for respiratory symptoms with
signiﬁcant neurological improvement. Follow-up neuroimaging
was not performed due to sedation risks. It is unclear whether the
improvement was achieved by steroid therapy or as the natural
progression of the disease. Corticosteroids have been used
occasionally in patients with CACH/VWM (van der Knaap
et al., 1993); however, the effect of immunomodulation in
CACH/VWM has yet to be determined.
Five genes that encode eIF2B are associated with CACH/
VWM in an autosomal recessive manner (Leegwater et al.,
2001). Although certain EIF2B5 variants are associated with
milder or more severe diseases, the age of onset and survival
are not signiﬁcantly different among the patients with pathogenic
variants in EIF2B1, EIF2B2, EIF2B3, EIF2B4, or EIF2B5
(Hamilton et al., 2018). The patients who harbor the same
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pathogenic variants are likely to have similar disease courses, with
the exception of milder phenotype, indicating a certain degree of
genotype–phenotype correlation (Hamilton et al., 2018).
In eukaryotic cells, eIF2B acts as a guanine nucleotide
exchange factor for eIF2. The formation of eIF2-GTP is
required for translation initiation (Pavitt, 2005). eIF2B also
plays a role in integrated stress response (ISR) (Marintchev
and Ito, 2020). Stress-induced kinase phosphorylate eIF2, in
turn, acts as a competitive inhibitor to eIF2B. Inhibition of
eIF2B activates ISR which promotes both proapoptotic and
pro-survival pathways (Marintchev and Ito, 2020).
Dysregulated ISR plays a key role in CACH/VWM. Clinical
trials for CACH/VWM are developed to target proteins in
these pathways (van der Knaap et al., 2022).
In the past, the diagnosis of leukodystrophies relies mostly on the
clinical course and brain imaging. Brain MRI is a crucial diagnostic
step and helps determine the subgroup of leukodystrophies;
however, the characteristics of brain MRI may not be able to
distinguish speciﬁc leukodystrophies (Bonkowsky et al., 2021).
The recent rapid development of next-generation sequencing
facilitates the diagnosis of rare inherited leukodystrophies. A
recent study demonstrates that whole-exome sequencing in
patients with persistently unresolved white matter abnormalities
yielded a diagnostic rate of 42% (Vanderver et al., 2016). We expect
that the availability of clinical genome sequencing will increase the
yield of genetic diagnoses in patients with leukodystrophies.
In conclusion, we report a patient with leukodystrophy.
CACH/VWM was diagnosed based on targeted sequencing,
elucidating the role of genetic diagnosis in patients with
leukodystrophies.
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